Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Research

Five-year change of clinical and complications profile of diabetic patients under primary care: a population-based longitudinal study on 127,977 diabetic patients

Authors: Colman Siu Cheung Fung, Eric Yuk Fai Wan, Fangfang Jiao, Cindy Lo Kuen Lam

Published in: Diabetology & Metabolic Syndrome | Issue 1/2015

Login to get access

Abstract

Background

Number of diabetic patients under public primary care in Hong Kong rose from 150,157 (2009) to 173,015 (2013). This study aimed to track the 5-year change of their outcomes and care standard after the introduction of quality enhancement programmes.

Methods

Longitudinal study was conducted on a group of diabetic patients who received continuous care under public primary care between 2009 and 2013. Socio-demographic and clinical data was retrieved from central database. The standard of care in terms of proportion of patients achieving haemoglobin A1c (HbA1c), systolic and diastolic blood pressure (SBP and DBP), and low density lipoprotein-cholesterol (LDL-C) target levels, mean parameter changes, and 5-year cumulative incidence of major complications were assessed. Outcomes between 2009 and 2013 were compared by McNemar’s test for proportion of patients treated to targets and paired t-test for continuous outcome parameters.

Results

A group of 127,977 diabetic patients who had continuous follow-up between 2009 and 2013 were assessed. A significantly higher proportions of patients achieving targets of HbA1c (<7 %), SBP (<130 mmHg), DBP (<80 mmHg), LDL-C (<2.6 mmol/L), triglyceride (<1.7 mmol/L), and high density lipoprotein-cholesterol (>1.0 or 1.3 mmol/L) were observed (p < 0.001). There was a significant drop in the mean values of HbA1c (7.2–7.0 %), SBP (136.9–131.3 mmHg), DBP (75.4–72.1 mmHg), LDL-C (3.1–2.4 mmol/L), triglyceride (1.7–1.4 mmol/L), and body mass index (25.6–25.3 kg/m2). More patients (0.6 % raised to 3.5 %) used insulin in addition to their oral anti-diabetic drugs for their management, and a significant boost (from 9.0 to 55.0 %) was on statin use. 5-year cumulative incidence of any major diabetic complication was 6.2 %.

Conclusions

Standard of public primary care for diabetic patients enhanced from 2009 to 2013, as reflected by the improvement in outcomes of care. It could be related to the implementation of the territory-wide quality enhancement programmes in all public primary care clinics since 2009, with coverage increasing from 3.1 % (2009) to 81.9 % (2013).
Clinical trial number and registry: NCT02034695, ClinicalTrials.gov
Appendix
Available only for authorised users
Literature
1.
go back to reference International Diabetes Federation. The 6th edition of the IDF Diabetes Atlas; 2014. International Diabetes Federation. The 6th edition of the IDF Diabetes Atlas; 2014.
2.
go back to reference World Health Organization. Global status report on noncommunicable diseases 2010; 2011. World Health Organization. Global status report on noncommunicable diseases 2010; 2011.
3.
go back to reference Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes‐related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32(4):459–66.CrossRefPubMed Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes‐related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32(4):459–66.CrossRefPubMed
4.
go back to reference American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Supplement 1):S14–80.CrossRef American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Supplement 1):S14–80.CrossRef
5.
go back to reference Boon N, Boyle R, Bradbury K, Buckley J, Connolly S, Craig S, et al. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(Suppl 2):ii1–67.CrossRef Boon N, Boyle R, Bradbury K, Buckley J, Connolly S, Craig S, et al. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100(Suppl 2):ii1–67.CrossRef
6.
go back to reference National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). Royal College of Physicians (UK); 2008. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). Royal College of Physicians (UK); 2008.
7.
go back to reference Bhattacharyya OK, Estey EA, Cheng AY. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician. 2009;55(1):39–43.PubMedCentralPubMed Bhattacharyya OK, Estey EA, Cheng AY. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician. 2009;55(1):39–43.PubMedCentralPubMed
8.
go back to reference Chan B, Tsang M, Lee V, Lee K. Cost of Type 2 diabetes mellitus in Hong Kong Chinese. Int J Clin Pharmacol Ther. 2007;45(8):455–68.CrossRefPubMed Chan B, Tsang M, Lee V, Lee K. Cost of Type 2 diabetes mellitus in Hong Kong Chinese. Int J Clin Pharmacol Ther. 2007;45(8):455–68.CrossRefPubMed
9.
go back to reference Fung CS, Chin WY, Dai DS, Kwok RL, Tsui EL, Wan YF, et al. Evaluation of the quality of care of a multi-disciplinary risk factor assessment and management programme (RAMP) for diabetic patients. BMC Fam Pract. 2012;13(1):116.PubMedCentralCrossRefPubMed Fung CS, Chin WY, Dai DS, Kwok RL, Tsui EL, Wan YF, et al. Evaluation of the quality of care of a multi-disciplinary risk factor assessment and management programme (RAMP) for diabetic patients. BMC Fam Pract. 2012;13(1):116.PubMedCentralCrossRefPubMed
10.
11.
go back to reference Rothman AA, Wagner EH. Chronic illness management: what is the role of primary care? Ann Intern Med. 2003;138(3):256–61.CrossRefPubMed Rothman AA, Wagner EH. Chronic illness management: what is the role of primary care? Ann Intern Med. 2003;138(3):256–61.CrossRefPubMed
14.
go back to reference Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA. 2002;288(15):1909–14.CrossRefPubMed Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA. 2002;288(15):1909–14.CrossRefPubMed
15.
go back to reference Macinko J, Starfield B, Shi L. The contribution of primary care systems to health outcomes within Organization for Economic Cooperation and Development (OECD) countries, 1970–1998. Health Serv Res. 2003;38(3):831–65.PubMedCentralCrossRefPubMed Macinko J, Starfield B, Shi L. The contribution of primary care systems to health outcomes within Organization for Economic Cooperation and Development (OECD) countries, 1970–1998. Health Serv Res. 2003;38(3):831–65.PubMedCentralCrossRefPubMed
16.
go back to reference Singh D. How can chronic disease management programmes operate across care settings and providers. Copenhagen: Regional Office for Europe of the World Health Organization, European Observatory on Health Systems and Policies; 2008. Singh D. How can chronic disease management programmes operate across care settings and providers. Copenhagen: Regional Office for Europe of the World Health Organization, European Observatory on Health Systems and Policies; 2008.
17.
go back to reference Hill A, Griffiths S, Gillam S. Public health and primary care: partners in population health. Oxford, New York: Oxford University Press; 2007.CrossRef Hill A, Griffiths S, Gillam S. Public health and primary care: partners in population health. Oxford, New York: Oxford University Press; 2007.CrossRef
20.
go back to reference Health and Social Care Information Centre. National Diabetes Audit 2012–2013 report 1: care processes and treatment targets; 2014. Health and Social Care Information Centre. National Diabetes Audit 2012–2013 report 1: care processes and treatment targets; 2014.
21.
go back to reference Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999–2010. N Engl J Med. 2013;368(17):1613–24.CrossRefPubMed Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999–2010. N Engl J Med. 2013;368(17):1613–24.CrossRefPubMed
22.
go back to reference Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.PubMedCentralCrossRefPubMed Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.PubMedCentralCrossRefPubMed
23.
go back to reference Chen C, Chang M, Hsieh M, Huang C, Liao L, Li T. Evaluation of perception of insulin therapy among Chinese patients with type 2 diabetes mellitus. Diabetes Metabol. 2011;37(5):389–94.CrossRef Chen C, Chang M, Hsieh M, Huang C, Liao L, Li T. Evaluation of perception of insulin therapy among Chinese patients with type 2 diabetes mellitus. Diabetes Metabol. 2011;37(5):389–94.CrossRef
24.
go back to reference Nakatani Y, Matsumura M, Monden T, Aso Y, Nakamoto T. Improvement of glycemic control by re-education in insulin injection technique in patients with diabetes mellitus. Adv Ther. 2013;30(10):897–906.CrossRefPubMed Nakatani Y, Matsumura M, Monden T, Aso Y, Nakamoto T. Improvement of glycemic control by re-education in insulin injection technique in patients with diabetes mellitus. Adv Ther. 2013;30(10):897–906.CrossRefPubMed
25.
go back to reference Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–8.CrossRefPubMed Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–8.CrossRefPubMed
26.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.CrossRefPubMed
27.
go back to reference Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823–8.PubMedCentralCrossRefPubMed Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823–8.PubMedCentralCrossRefPubMed
28.
go back to reference Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM Jr, Kastelein J, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195.CrossRefPubMed Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM Jr, Kastelein J, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195.CrossRefPubMed
29.
go back to reference Group HPSC. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. ACC Curr J Rev. 2002;11(6):34–5. Group HPSC. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. ACC Curr J Rev. 2002;11(6):34–5.
30.
go back to reference Parvez A, Rafiq A, Ahmad N, Khan E. Relationship of glycaemia and triglycerides with BMI in diabetic patients. JAMC. 2009;22(2):164–6. Parvez A, Rafiq A, Ahmad N, Khan E. Relationship of glycaemia and triglycerides with BMI in diabetic patients. JAMC. 2009;22(2):164–6.
31.
go back to reference McAdams MA, Dam RM, Hu FB. Comparison of self-reported and measured BMI as correlates of disease markers in US adults. Obesity. 2007;15(1):188.CrossRefPubMed McAdams MA, Dam RM, Hu FB. Comparison of self-reported and measured BMI as correlates of disease markers in US adults. Obesity. 2007;15(1):188.CrossRefPubMed
32.
go back to reference Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–9.PubMedCentralCrossRefPubMed Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–9.PubMedCentralCrossRefPubMed
33.
go back to reference Chan W, Chan T, Luk W, Leung V, Li T, Critchley J. A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol. 1993;44(3):299–300.CrossRefPubMed Chan W, Chan T, Luk W, Leung V, Li T, Critchley J. A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol. 1993;44(3):299–300.CrossRefPubMed
34.
go back to reference Woo KS, Nicholls M. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40(2):141.PubMedCentralPubMed Woo KS, Nicholls M. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40(2):141.PubMedCentralPubMed
35.
go back to reference Vidt DG. Telmisartan, ramipril, or both in patients at high risk for vascular events. Curr Hypertens Rep. 2008;10(5):343–4.CrossRefPubMed Vidt DG. Telmisartan, ramipril, or both in patients at high risk for vascular events. Curr Hypertens Rep. 2008;10(5):343–4.CrossRefPubMed
37.
38.
go back to reference National Collaborating Centre for Chronic Conditions. Type 2 diabetes National clinical guideline for management in primary and secondary care (update): Royal College of Physicians; 2008. National Collaborating Centre for Chronic Conditions. Type 2 diabetes National clinical guideline for management in primary and secondary care (update): Royal College of Physicians; 2008.
39.
go back to reference Asia Pacific Cohort Studies Collaboration. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Commun Health. 2007;61:115–21.CrossRef Asia Pacific Cohort Studies Collaboration. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Commun Health. 2007;61:115–21.CrossRef
40.
go back to reference Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292(20):2495–9.CrossRefPubMed Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292(20):2495–9.CrossRefPubMed
41.
go back to reference Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167(11):1145–51.CrossRefPubMed Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167(11):1145–51.CrossRefPubMed
42.
go back to reference Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134–46.CrossRefPubMed Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134–46.CrossRefPubMed
43.
go back to reference Kong AP, Xu G, Brown N, So W-Y, Ma RC, Chan JC. Diabetes and its comorbidities—where East meets West. Nat Rev Endocrinol. 2013;9(9):537–47.CrossRefPubMed Kong AP, Xu G, Brown N, So W-Y, Ma RC, Chan JC. Diabetes and its comorbidities—where East meets West. Nat Rev Endocrinol. 2013;9(9):537–47.CrossRefPubMed
Metadata
Title
Five-year change of clinical and complications profile of diabetic patients under primary care: a population-based longitudinal study on 127,977 diabetic patients
Authors
Colman Siu Cheung Fung
Eric Yuk Fai Wan
Fangfang Jiao
Cindy Lo Kuen Lam
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-015-0072-x

Other articles of this Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue